Interestingly, pediatric recurrent osteosarcoma patients can receive innovative targeted treatments, in the context of basket trials; selpercatinib (NCT04320888) is tested in patients carrying RET gene alterations, reported to be present in 4% of osteosarcomas [99]. The gene discussed is RET; the disease is osteosarcoma.